Nervonic acid CAS#: 506-37-6; 凯望编码 (ChemWhat Code): 59032
Identification
| 英文名 | Nervonic acid |
| IUPAC Name | (Z)-tetracos-15-enoic acid |
| 分子结构 |  |
| CAS编号 | 506-37-6 |
| 别名 | Nervonic acid 506-37-6 cis-15-tetracosenoic acid (Z)-tetracos-15-enoic acid selacholeic acid (15Z)-Tetracosenoic acid Nevonic acid 15-Tetracosenoic acid cis-selacholeic acid (Z)-15-Tetracosenoic acid Nervonsaeure 15Z-tetracosenoic acid (15Z)-tetracos-15-enoic acid UNII-91OQS788BE 91OQS788BE CHEBI:44247 15cis-tetracosenoic acid 15-Tetracosenoic acid, (15Z)- (15e)-Tetracos-15-Enoic Acid cis-Delta(15)-tetracosenoic acid DTXSID801009308 15-TETRACOSENOIC ACID, CIS- MFCD00010507 TETRACOSENOIC ACID, (15Z)- 15-TETRACOSENOIC ACID, (Z)- FA 24:1 (Z)-15-tetracosenoate 24:1(N-9) (15Z)-tetracos-15-enoate cis-Delta(15)-tetracosenoate C24:1n-9 selacholeate cis-selacholeate 15-Tetracosenoate 15Z-tetracosenoate cis-15-Teracosenoate cis-15-Tetracosenate ISOCONAZOLENITRATE z-15-Tetracosenoic acid cis-15-Teracosenoic acid cis-15-Tetracosenic acid Fatty Acid 24:1 n-9 (Z)-tetracos-15-enoicacid NERVONIC ACID [DSC] SCHEMBL21103 NERVONIC ACID [WHO-DD] Tetracosenoic acid, 15-(Z)- CHEMBL1173379 DTXCID001436135 Nervonic acid, analytical standard AMY22585 BCP28714 HY-N2526 LMFA01030092 s6430 AKOS027320479 FD10484 Nervonic acid, >=99% (capillary GC) NCGC00484930-01 AC-33771 AS-59819 FA(24:1) FA(24:1(15Z)) Nervonic acid, analytical reference material CS-0022797 NS00015174 T1642 C08323 Q414231 NERVONIC ACID (CONSTITUENT OF BORAGE SEED OIL) 3F0366A4-A342-402E-B731-D54879FC86E7 |
| 分子式 | C24H46O2 |
| 分子量 | 366.6 |
| InChI | InChI=1S/C24H46O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24(25)26/h9-10H,2-8,11-23H2,1H3,(H,25,26)/b10-9- |
| InChI Key | GWHCXVQVJPWHRF-KTKRTIGZSA-N |
| Isomeric SMILES | CCCCCCCC/C=C\CCCCCCCCCCCCCC(=O)O |
| Patent Information | ||
| Patent ID | Title | Publication Date |
| CN115417759 | Method for preparing nervonic acid from erucic acid oxidation-reduction active ester | 2022 |
| US5959131 | Nutritionally superior fat for food compositions | 1999 |
Physical Data
| Appearance | Oily or white powder |
| Melting Point, °C | Solvent (Melting Point) |
| 41.2 | |
| 40 – 41 | |
| 40.5 – 42.1 | acetone |
| 42.87 | |
| 39 | |
| 41.1 | acetone |
| 40.5 – 41 | acetone |
| Boiling Point, °C |
| 225 – 235 |
| Density, g·cm-3 |
| 0.95 |
Spectra
| Description (NMR Spectroscopy) | Nucleus (NMR Spectroscopy) | Solvents (NMR Spectroscopy) |
| Chemical shifts, Spectrum | 1H | chloroform-d1 |
| Chemical shifts, Spectrum | 13C | chloroform-d1 |
| Chemical shifts | 1H | chloroform-d1 |
| Chemical shifts | 13C | chloroform-d1 |
| Description (IR Spectroscopy) | Solvent (IR Spectroscopy) | Temperature (IR Spectroscopy), °C |
| Bands | ||
| Bands | chloroform, methanol | 25 |
Route of Synthesis (ROS)
| Conditions | Yield |
| Stage #1: Nervonic acid With 1,1′-carbonyldiimidazole In dichloromethane at 20℃; for 2h; Stage #2: benzylamine With dmap In dichloromethane at 20℃; for 18h; Experimental Procedure 4.1.1. N-benzylpalmitamide (3a) General procedure: To a solution of palmitic acid (300mg, 1.17mmol) in dichloromethane (DCM, 10mL) was added 1,1′-carbonyldiimdazole (209mg, 1.29mmol). The reaction was stirred at room temperature for 2h. The reaction mixture was slowly added to a solution of benzylamine (153μL, 1.40mmol) and 4-dimethylaminopyridine (14mg, 0.12mmol) in dichloromethane (5mL). The solution was stirred at room temperature for 18h. DCM (100mL) and saturated aqueous NaHCO3 (30mL) were added to the reaction mixture. The organic layer was separated and washed with H2O (30mL), brine (30mL), dried over anhyd sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude was purified by flash chromatography on silica gel eluting with hexane/EtOAc (3:1, v/v) to give the title compound as a white solid (578mg, 86%). Mp 85-87° [lit.45 mp 94.5-95°, and46 fp 95.1°]; 1H NMR (400MHz, CDCl3) δ 7.32-7.36 (m, 2H), 7.26-7.30 (m, 3H), 5.72 (br s, 1H), 4.45 (d, J=6.0Hz, 2H), 2.21 (t, J=7.2Hz, 2H), 1.61-1.67 (m, 2H), 1.25-1.34 (m, 24H), 0.88 (t, J=6.8Hz, 3H); 13C NMR (CDCl3, 100MHz) δ 173.21, 138.66, 128.92, 128.05, 127.71, 43.80, 37.06, 32.16, 29.92, 29.89, 29.84, 29.73, 29.59, 29.56, 26.01, 22.93, 14.36; LCMS, C23H39NO, [M+H]: 346. | 94% |
| With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 1.5h; |
Safety and Hazards
| Pictogram(s) |  |
| Signal | Warning |
| GHS Hazard Statements | H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation] |
| Precautionary Statement Codes | P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (The corresponding statement to each P-code can be found at the GHS Classification page.) |
Other Data
| Druglikeness | |
| Lipinski rules component | |
| 分子量 | 94.116 |
| logP | -0.047 |
| HBA | 2 |
| HBD | 1 |
| Matching Lipinski Rules | 4 |
| Veber rules component | |
| Polar Surface Area (PSA) | 38.91 |
| Rotatable Bond (RotB) | 0 |
| Matching Veber Rules | 2 |
| Bioactivity |
| In vitro: Efficacy |
| Quantitative Results |
| pX | Parameter | Value (qual) | Value (quant) | Unit | Target | Effect |
| 8.05 | pIC50(Virus replication) | = | 8.05 | antiviral agent | ||
| 8.05 | pIC50 | = | 8.05 | Topoisomerase dna ii 180kda (Beta) [Human immunodeficiency virus 1]:Wild | ||
| 5.65 | EC90(Amount Of P24 Protein) | > | 20 | µM | ||
| 5.48 | IC50(protease activity) | 3.3 | µM | |||
| 4.63 | IC50 | 23.45 | μg | antifungal agent | ||
| 4.59 | IC50 | 2.45 | μg/ml | antifungal agent | ||
| 4.45 | IC50 | 3.33 | μg/ml | antifungal agent | ||
| 4 | stimulation rate | Active | High voltage-activated calcium channel [rat]:Wild | |||
| 3.44 | IC50 | 34.55 | μg/ml | antifungal agent |
| Druglikeness | |
| Lipinski rules component | |
| 分子量 | 366.628 |
| logP | 11.606 |
| HBA | 2 |
| HBD | 1 |
| Matching Lipinski Rules | 3 |
| Veber rules component | |
| Polar Surface Area (PSA) | 37.3 |
| Rotatable Bond (RotB) | 21 |
| Matching Veber Rules | 2 |
| Use Pattern |
| Nervonic acid is an important monounsaturated fatty acid in the brain and is essential for brain health. It can help with the growth and regeneration of nerve cells, improving the function and structure of cell membranes. Although the human body can synthesize nervonic acid, the efficiency is low. Therefore, external supplementation is necessary to meet the needs of the brain and nerve development. |
试剂采购 | |
| 没有试剂厂商? | 向凯望发送快速询价 |
| 想要被列为试剂厂商? (付费服务) | 点击这里联系凯望 |
认证生产商 | |
| Caming Pharmaceutical Limited | http://www.caming.com/ |
| 想要被列为认证生产商 (需要通过认证)? | 请下载并填写 这份表格并发邮件到approved-manufacturers@chemwhat.com |
其他供应商 | |
| Watson International Limited | 访问Watson官网 |
如需其他帮助，请联系我们 | |
| 联系我们获取其它信息或服务 | 点击这里联系凯望 |